<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"	
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	xmlns:media="http://search.yahoo.com/mrss/"
	>
<channel>
	<title>Pharmacists &#187; The Doctor&#039;s Channel</title>
	<atom:link href="http://www.thedoctorschannel.com/channels/pharmacists/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.thedoctorschannel.com</link>
	<description>Internet TV for Doctors</description>
	<lastBuildDate>Wed, 16 May 2012 23:34:19 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.1.2</generator>
			<item>
		<title>Sumatriptan-naproxen combo effective for adolescent migraine</title>
		<link>http://www.thedoctorschannel.com/view/sumatriptan-naproxen-combo-effective-for-adolescent-migraine/</link>
		<pubDate>Wed, 16 May 2012 15:16:39 +0000</pubDate> 
				<category><![CDATA[Family Medicine]]></category>
		<category><![CDATA[Featured]]></category>
		<category><![CDATA[Home Page Featured]]></category>
		<category><![CDATA[Neurology & Neurosurgery]]></category>
		<category><![CDATA[Nurses/NP/PA]]></category>
		<category><![CDATA[Pediatrics]]></category>
		<category><![CDATA[Pharmacists]]></category>
		<category><![CDATA[Reuters Health • The Doctor's Channel Daily Newscast]]></category>
		<category><![CDATA[migraine]]></category>
		<category><![CDATA[naproxen]]></category>
		<category><![CDATA[sumatriptan]]></category>
		<guid isPermaLink="false">http://www.thedoctorschannel.com/?p=31826</guid>
		<description><![CDATA[NEW YORK (Reuters Health) – Based on the results of a randomized, double-blind trial, more adolescents with acute migraine become pain-free within 2 hours after taking a combination of sumatriptan and naproxen sodium compared to placebo, according to a report in the June issue of Pediatrics. “This study constitutes the first large-scale, placebo-controlled evidence for -]]></description>
		
			<media:content duration="1:30" medium="video">
		<media:title><![CDATA[Sumatriptan-naproxen combo effective for adolescent migraine]]></media:title>
	<media:description><![CDATA[NEW YORK (Reuters Health) – Based on the results of a randomized, double-blind trial, more adolescents with acute migraine become pain-free within 2 hours after taking a combination of sumatriptan and naproxen sodium compared to placebo, according to a report in the June issue of Pediatrics. “This study constitutes the first large-scale, placebo-controlled evidence for -]]></media:description>
	<media:player url="http://www.thedoctorschannel.com/view/sumatriptan-naproxen-combo-effective-for-adolescent-migraine/" />
		<media:thumbnail url= "http://www.thedoctorschannel.com/wp-content/uploads/2012/05/Thumbnail_20120516clin001.jpg"/>
	<media:keywords><![CDATA[migraine,naproxen,sumatriptan]]></media:keywords>
<media:copyright>The Doctor's Channel</media:copyright>
	</media:content>
			</item>
			<item>
		<title>ACE inhibitors tied to increased angioedema risk</title>
		<link>http://www.thedoctorschannel.com/view/ace-inhibitors-tied-to-increased-angioedema-risk/</link>
		<pubDate>Tue, 15 May 2012 18:53:02 +0000</pubDate> 
				<category><![CDATA[Family Medicine]]></category>
		<category><![CDATA[Internal Medicine]]></category>
		<category><![CDATA[Nephrology]]></category>
		<category><![CDATA[Nurses/NP/PA]]></category>
		<category><![CDATA[Pharmacists]]></category>
		<category><![CDATA[Reuters Health • The Doctor's Channel Daily Newscast]]></category>
		<category><![CDATA[ACE inhibitors]]></category>
		<category><![CDATA[angioedema]]></category>
		<category><![CDATA[angiotensin]]></category>
		<category><![CDATA[ARB]]></category>
		<guid isPermaLink="false">http://www.thedoctorschannel.com/?p=31793</guid>
		<description><![CDATA[NEW YORK (Reuters Health) &#8211; Pooled data suggest that use of renin–angiotensin system (RAS) inhibitors, particularly angiotensin converting enzyme (ACE) inhibitors may increase the risk of angioedema, researchers report in an April 20th on-line paper in the American Journal of Cardiology. Nevertheless, Dr. Franz H. Messerli told Reuters Health by email, &#8220;ACE inhibitors are among -]]></description>
		
			<media:content duration="1:29" medium="video">
		<media:title><![CDATA[ACE inhibitors tied to increased angioedema risk]]></media:title>
	<media:description><![CDATA[NEW YORK (Reuters Health) &#8211; Pooled data suggest that use of renin–angiotensin system (RAS) inhibitors, particularly angiotensin converting enzyme (ACE) inhibitors may increase the risk of angioedema, researchers report in an April 20th on-line paper in the American Journal of Cardiology. Nevertheless, Dr. Franz H. Messerli told Reuters Health by email, &#8220;ACE inhibitors are among -]]></media:description>
	<media:player url="http://www.thedoctorschannel.com/view/ace-inhibitors-tied-to-increased-angioedema-risk/" />
		<media:thumbnail url= "http://www.thedoctorschannel.com/wp-content/uploads/2012/05/Thumbnail_20120515clinc003.jpg"/>
	<media:keywords><![CDATA[ACE inhibitors,angioedema,angiotensin,ARB]]></media:keywords>
<media:copyright>The Doctor's Channel</media:copyright>
	</media:content>
			</item>
			<item>
		<title>Higher beta-blocker dose lowers mortality in heart failure patients</title>
		<link>http://www.thedoctorschannel.com/view/higher-beta-blocker-dose-lowers-mortality-in-heart-failure-patients-2/</link>
		<pubDate>Wed, 09 May 2012 21:43:01 +0000</pubDate> 
				<category><![CDATA[Cardiology]]></category>
		<category><![CDATA[Family Medicine]]></category>
		<category><![CDATA[Hospitalist]]></category>
		<category><![CDATA[Internal Medicine]]></category>
		<category><![CDATA[Nurses/NP/PA]]></category>
		<category><![CDATA[Pharmacists]]></category>
		<category><![CDATA[Reuters Health • The Doctor's Channel Daily Newscast]]></category>
		<category><![CDATA[beta-blocker]]></category>
		<category><![CDATA[Heart Failure]]></category>
		<guid isPermaLink="false">http://www.thedoctorschannel.com/?p=31316</guid>
		<description><![CDATA[NEW YORK (Reuters Health) – Confirming recommendations, titrating beta-blocker dosage in ambulatory patients with heart failure up to an equivalent of 50 mg/d carvedilol reduces all-cause deaths and hospitalizations, according to a report in the July 17 issue of the Journal of the American College of Cardiology. “There was no increase in bradycardia with higher -]]></description>
		
			<media:content duration="1:27" medium="video">
		<media:title><![CDATA[Higher beta-blocker dose lowers mortality in heart failure patients]]></media:title>
	<media:description><![CDATA[NEW YORK (Reuters Health) – Confirming recommendations, titrating beta-blocker dosage in ambulatory patients with heart failure up to an equivalent of 50 mg/d carvedilol reduces all-cause deaths and hospitalizations, according to a report in the July 17 issue of the Journal of the American College of Cardiology. “There was no increase in bradycardia with higher -]]></media:description>
	<media:player url="http://www.thedoctorschannel.com/view/higher-beta-blocker-dose-lowers-mortality-in-heart-failure-patients-2/" />
		<media:thumbnail url= "http://www.thedoctorschannel.com/wp-content/uploads/2012/05/Thumbnail_20120509clin001.jpg"/>
	<media:keywords><![CDATA[beta-blocker,Heart Failure]]></media:keywords>
<media:copyright>The Doctor's Channel</media:copyright>
	</media:content>
			</item>
			<item>
		<title>Metformin may prevent liver cancer in type 2 diabetes</title>
		<link>http://www.thedoctorschannel.com/view/metformin-may-prevent-liver-cancer-in-type-2-diabetes/</link>
		<pubDate>Wed, 09 May 2012 21:35:04 +0000</pubDate> 
				<category><![CDATA[Diabetes]]></category>
		<category><![CDATA[Endocrinology]]></category>
		<category><![CDATA[Family Medicine]]></category>
		<category><![CDATA[Internal Medicine]]></category>
		<category><![CDATA[Nurses/NP/PA]]></category>
		<category><![CDATA[Oncology]]></category>
		<category><![CDATA[Pharmacists]]></category>
		<category><![CDATA[Reuters Health • The Doctor's Channel Daily Newscast]]></category>
		<category><![CDATA[cancer]]></category>
		<category><![CDATA[colorectal]]></category>
		<category><![CDATA[diabetes]]></category>
		<category><![CDATA[liver]]></category>
		<category><![CDATA[metformin]]></category>
		<guid isPermaLink="false">http://www.thedoctorschannel.com/?p=31303</guid>
		<description><![CDATA[NEW YORK (Reuters Health) – Metformin appears to lower the risk of developing liver cancer in patients with type 2 diabetes, according to the results of a meta-analysis reported in the July issue of the Journal of Clinical Endocrinology and Metabolism. However, “Further investigation, including mechanistic studies, well-designed cohort studies, and possibly controlled trials, is -]]></description>
		
			<media:content duration="1:22" medium="video">
		<media:title><![CDATA[Metformin may prevent liver cancer in type 2 diabetes]]></media:title>
	<media:description><![CDATA[NEW YORK (Reuters Health) – Metformin appears to lower the risk of developing liver cancer in patients with type 2 diabetes, according to the results of a meta-analysis reported in the July issue of the Journal of Clinical Endocrinology and Metabolism. However, “Further investigation, including mechanistic studies, well-designed cohort studies, and possibly controlled trials, is -]]></media:description>
	<media:player url="http://www.thedoctorschannel.com/view/metformin-may-prevent-liver-cancer-in-type-2-diabetes/" />
		<media:thumbnail url= "http://www.thedoctorschannel.com/wp-content/uploads/2012/05/Thumbnail_20120509clin006.jpg"/>
	<media:keywords><![CDATA[cancer,colorectal,diabetes,liver,metformin]]></media:keywords>
<media:copyright>The Doctor's Channel</media:copyright>
	</media:content>
			</item>
			<item>
		<title>Low-dose aspirin may prevent nonvascular deaths</title>
		<link>http://www.thedoctorschannel.com/view/low-dose-aspirin-may-prevent-nonvascular-deaths-2/</link>
		<pubDate>Mon, 30 Apr 2012 22:50:46 +0000</pubDate> 
				<category><![CDATA[Cardiology]]></category>
		<category><![CDATA[Family Medicine]]></category>
		<category><![CDATA[Internal Medicine]]></category>
		<category><![CDATA[Nurses/NP/PA]]></category>
		<category><![CDATA[Oncology]]></category>
		<category><![CDATA[Pharmacists]]></category>
		<category><![CDATA[Reuters Health • The Doctor's Channel Daily Newscast]]></category>
		<category><![CDATA[aspirin]]></category>
		<category><![CDATA[cancer]]></category>
		<category><![CDATA[nonvascular mortality]]></category>
		<guid isPermaLink="false">http://www.thedoctorschannel.com/?p=30383</guid>
		<description><![CDATA[NEW YORK (Reuters Health) – Daily low-dose aspirin reduces not only cardiovascular mortality but also nonvascular mortality – and cancer mortality in particular &#8212; after relatively short duration of treatment, according to the results of a meta-analysis published in the American Journal of Medicine online April 18. “The impact of widespread aspirin use on cancer -]]></description>
		
			<media:content duration="1:27" medium="video">
		<media:title><![CDATA[Low-dose aspirin may prevent nonvascular deaths]]></media:title>
	<media:description><![CDATA[NEW YORK (Reuters Health) – Daily low-dose aspirin reduces not only cardiovascular mortality but also nonvascular mortality – and cancer mortality in particular &#8212; after relatively short duration of treatment, according to the results of a meta-analysis published in the American Journal of Medicine online April 18. “The impact of widespread aspirin use on cancer -]]></media:description>
	<media:player url="http://www.thedoctorschannel.com/view/low-dose-aspirin-may-prevent-nonvascular-deaths-2/" />
		<media:thumbnail url= "http://www.thedoctorschannel.com/wp-content/uploads/2012/04/Thumbnail_20120430clin002.jpg"/>
	<media:keywords><![CDATA[aspirin,cancer,nonvascular mortality]]></media:keywords>
<media:copyright>The Doctor's Channel</media:copyright>
	</media:content>
			</item>
			<item>
		<title>Benzodiazepine use safe during lactation</title>
		<link>http://www.thedoctorschannel.com/view/benzodiazepine-use-safe-during-lactation/</link>
		<pubDate>Fri, 27 Apr 2012 19:13:04 +0000</pubDate> 
				<category><![CDATA[Family Medicine]]></category>
		<category><![CDATA[Nurses/NP/PA]]></category>
		<category><![CDATA[Ob/Gyn]]></category>
		<category><![CDATA[Pediatrics]]></category>
		<category><![CDATA[Pharmacists]]></category>
		<category><![CDATA[Reuters Health • The Doctor's Channel Daily Newscast]]></category>
		<category><![CDATA[benzodiazepine]]></category>
		<category><![CDATA[breast feeding]]></category>
		<category><![CDATA[lactation]]></category>
		<category><![CDATA[nursing]]></category>
		<guid isPermaLink="false">http://www.thedoctorschannel.com/?p=30284</guid>
		<description><![CDATA[NEW YORK (Reuters Health) &#8211; The sedative effects of benzodiazepine exposure through breast milk appear to present minimal risk of central nervous system (CNS) depression in infants, results of a new study suggest. Currently, breastfeeding is not contraindicated in women using psychotropic medications such as benzodiazepines. Dr. Gideon Koren from the Hospital for Sick Children, -]]></description>
		
			<media:content duration="1:35" medium="video">
		<media:title><![CDATA[Benzodiazepine use safe during lactation]]></media:title>
	<media:description><![CDATA[NEW YORK (Reuters Health) &#8211; The sedative effects of benzodiazepine exposure through breast milk appear to present minimal risk of central nervous system (CNS) depression in infants, results of a new study suggest. Currently, breastfeeding is not contraindicated in women using psychotropic medications such as benzodiazepines. Dr. Gideon Koren from the Hospital for Sick Children, -]]></media:description>
	<media:player url="http://www.thedoctorschannel.com/view/benzodiazepine-use-safe-during-lactation/" />
		<media:thumbnail url= "http://www.thedoctorschannel.com/wp-content/uploads/2012/04/Thumbnail_20120427clin003.jpg"/>
	<media:keywords><![CDATA[benzodiazepine,breast feeding,lactation,nursing]]></media:keywords>
<media:copyright>The Doctor's Channel</media:copyright>
	</media:content>
			</item>
			<item>
		<title>Twice-daily aclidinium improves bronchodilation in COPD patients</title>
		<link>http://www.thedoctorschannel.com/view/twice-daily-aclidinium-improves-bronchodilation-in-copd-patients/</link>
		<pubDate>Tue, 17 Apr 2012 20:08:49 +0000</pubDate> 
				<category><![CDATA[Family Medicine]]></category>
		<category><![CDATA[Hospitalist]]></category>
		<category><![CDATA[Internal Medicine]]></category>
		<category><![CDATA[Nurses/NP/PA]]></category>
		<category><![CDATA[Pharmacists]]></category>
		<category><![CDATA[Pulmonary Medicine]]></category>
		<category><![CDATA[Reuters Health • The Doctor's Channel Daily Newscast]]></category>
		<category><![CDATA[Aclidinium]]></category>
		<category><![CDATA[COPD]]></category>
		<guid isPermaLink="false">http://www.thedoctorschannel.com/?p=28292</guid>
		<description><![CDATA[NEW YORK (Reuters Health) – In patients with moderate-to-severe chronic obstructive pulmonary disease, twice daily inhalation of either 200 or 400 mcg aclidinium bromide significantly improves FEV1, and results are sustained after 24 weeks, according to a report in the European Respiratory Journal online March 22. “With both aclidinium doses, the incidence of anticholinergic adverse -]]></description>
		
			<media:content duration="1:31" medium="video">
		<media:title><![CDATA[Twice-daily aclidinium improves bronchodilation in COPD patients]]></media:title>
	<media:description><![CDATA[NEW YORK (Reuters Health) – In patients with moderate-to-severe chronic obstructive pulmonary disease, twice daily inhalation of either 200 or 400 mcg aclidinium bromide significantly improves FEV1, and results are sustained after 24 weeks, according to a report in the European Respiratory Journal online March 22. “With both aclidinium doses, the incidence of anticholinergic adverse -]]></media:description>
	<media:player url="http://www.thedoctorschannel.com/view/twice-daily-aclidinium-improves-bronchodilation-in-copd-patients/" />
		<media:thumbnail url= "http://www.thedoctorschannel.com/wp-content/uploads/2012/04/Thumbnail_20120417drgd002.jpg"/>
	<media:keywords><![CDATA[Aclidinium,COPD]]></media:keywords>
<media:copyright>The Doctor's Channel</media:copyright>
	</media:content>
			</item>
			<item>
		<title>CHF mortality risk not higher with losartan than candesartan</title>
		<link>http://www.thedoctorschannel.com/view/chf-mortality-risk-not-higher-with-losartan-than-candesartan/</link>
		<pubDate>Wed, 11 Apr 2012 22:47:54 +0000</pubDate> 
				<category><![CDATA[Cardiology]]></category>
		<category><![CDATA[Internal Medicine]]></category>
		<category><![CDATA[Pharmacists]]></category>
		<category><![CDATA[Reuters Health • The Doctor's Channel Daily Newscast]]></category>
		<category><![CDATA[ARB]]></category>
		<category><![CDATA[candesartan]]></category>
		<category><![CDATA[CHF]]></category>
		<category><![CDATA[congestive heart failure]]></category>
		<category><![CDATA[Losartan]]></category>
		<guid isPermaLink="false">http://www.thedoctorschannel.com/?p=27986</guid>
		<description><![CDATA[NEW YORK (Reuters Health) – Contrary to previous reports, losartan is not associated with increased mortality risk in patients with heart failure, according the results of a Danish investigation reported in the Journal of the American Medical Association for April 11. “There was a decreasing risk of mortality with increasing losartan dose; and no significantly -]]></description>
		
			<media:content duration="1:29" medium="video">
		<media:title><![CDATA[CHF mortality risk not higher with losartan than candesartan]]></media:title>
	<media:description><![CDATA[NEW YORK (Reuters Health) – Contrary to previous reports, losartan is not associated with increased mortality risk in patients with heart failure, according the results of a Danish investigation reported in the Journal of the American Medical Association for April 11. “There was a decreasing risk of mortality with increasing losartan dose; and no significantly -]]></media:description>
	<media:player url="http://www.thedoctorschannel.com/view/chf-mortality-risk-not-higher-with-losartan-than-candesartan/" />
		<media:thumbnail url= "http://www.thedoctorschannel.com/wp-content/uploads/2012/04/Thumbnail_20120410clin0061.jpg"/>
	<media:keywords><![CDATA[ARB,candesartan,CHF,congestive heart failure,Losartan]]></media:keywords>
<media:copyright>The Doctor's Channel</media:copyright>
	</media:content>
			</item>
			<item>
		<title>Cigarette smoking potentiates effects of clopidogrel in diabetics</title>
		<link>http://www.thedoctorschannel.com/view/cigarette-smoking-potentiates-effects-of-clopidogrel-in-diabetics/</link>
		<pubDate>Fri, 06 Apr 2012 21:03:18 +0000</pubDate> 
				<category><![CDATA[Cardiology]]></category>
		<category><![CDATA[Diabetes]]></category>
		<category><![CDATA[Endocrinology]]></category>
		<category><![CDATA[Family Medicine]]></category>
		<category><![CDATA[Internal Medicine]]></category>
		<category><![CDATA[Medical Students]]></category>
		<category><![CDATA[Nurses/NP/PA]]></category>
		<category><![CDATA[Pharmacists]]></category>
		<category><![CDATA[Reuters Health • The Doctor's Channel Daily Newscast]]></category>
		<category><![CDATA[clopidogrel]]></category>
		<category><![CDATA[diabetes]]></category>
		<category><![CDATA[Smoking]]></category>
		<guid isPermaLink="false">http://www.thedoctorschannel.com/?p=27756</guid>
		<description><![CDATA[NEW YORK (Reuters Health) – Cigarette smoking enhanced the effects of clopidogrel in a study of diabetics with coronary artery disease. Accordingly, smokers were less likely to experience high on-treatment platelet reactivity (HPR), the researchers reported in the March issue of JACC: Cardiovascular Interventions. “To the best of our knowledge the present investigation is the -]]></description>
		
			<media:content duration="1:36" medium="video">
		<media:title><![CDATA[Cigarette smoking potentiates effects of clopidogrel in diabetics]]></media:title>
	<media:description><![CDATA[NEW YORK (Reuters Health) – Cigarette smoking enhanced the effects of clopidogrel in a study of diabetics with coronary artery disease. Accordingly, smokers were less likely to experience high on-treatment platelet reactivity (HPR), the researchers reported in the March issue of JACC: Cardiovascular Interventions. “To the best of our knowledge the present investigation is the -]]></media:description>
	<media:player url="http://www.thedoctorschannel.com/view/cigarette-smoking-potentiates-effects-of-clopidogrel-in-diabetics/" />
		<media:thumbnail url= "http://www.thedoctorschannel.com/wp-content/uploads/2012/04/Thumbnail_20120319epid005.jpg"/>
	<media:keywords><![CDATA[clopidogrel,diabetes,Smoking]]></media:keywords>
<media:copyright>The Doctor's Channel</media:copyright>
	</media:content>
			</item>
			<item>
		<title>Oral bisphosphonates linked to ocular side effects</title>
		<link>http://www.thedoctorschannel.com/view/oral-bisphosphonates-linked-to-ocular-side-effects/</link>
		<pubDate>Wed, 04 Apr 2012 22:06:07 +0000</pubDate> 
				<category><![CDATA[Endocrinology]]></category>
		<category><![CDATA[Family Medicine]]></category>
		<category><![CDATA[Internal Medicine]]></category>
		<category><![CDATA[Medical Students]]></category>
		<category><![CDATA[Nurses/NP/PA]]></category>
		<category><![CDATA[Ophthalmology]]></category>
		<category><![CDATA[Orthopedics]]></category>
		<category><![CDATA[Pharmacists]]></category>
		<category><![CDATA[Reuters Health • The Doctor's Channel Daily Newscast]]></category>
		<category><![CDATA[bisphosphonates]]></category>
		<category><![CDATA[scleritis]]></category>
		<category><![CDATA[uveitis]]></category>
		<guid isPermaLink="false">http://www.thedoctorschannel.com/?p=27636</guid>
		<description><![CDATA[NEW YORK (Reuters Health) – A Canadian study confirms an increased risk of uveitis and scleritis in first-time users of oral bisphosphonates. “Patients taking bisphosphonates must be familiar with the signs and symptoms of these conditions, so that they can immediately seek assessment by an ophthalmologist,” conclude the authors of the report in the Canadian -]]></description>
		
			<media:content duration="1:17" medium="video">
		<media:title><![CDATA[Oral bisphosphonates linked to ocular side effects]]></media:title>
	<media:description><![CDATA[NEW YORK (Reuters Health) – A Canadian study confirms an increased risk of uveitis and scleritis in first-time users of oral bisphosphonates. “Patients taking bisphosphonates must be familiar with the signs and symptoms of these conditions, so that they can immediately seek assessment by an ophthalmologist,” conclude the authors of the report in the Canadian -]]></media:description>
	<media:player url="http://www.thedoctorschannel.com/view/oral-bisphosphonates-linked-to-ocular-side-effects/" />
		<media:thumbnail url= "http://www.thedoctorschannel.com/wp-content/uploads/2012/04/Thumbnail_20120404clin003.jpg"/>
	<media:keywords><![CDATA[bisphosphonates,scleritis,uveitis]]></media:keywords>
<media:copyright>The Doctor's Channel</media:copyright>
	</media:content>
			</item>
	</channel>
</rss>
